Phthalates inhibit tamoxifen-induced apoptosis in MCF-7 human breast cancer cells

Journal of Toxicology and Environmental Health - Part A

Volumn 67, Issue 23-24, 2004, Pages 2025-2035

  In, Young Kim ^a,b   Soon, Young Han ^b   Moon, Aree ^a  

^a Duksung Women's University   (South Korea)

^b Korea Food and Drug Administration   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTROGEN RECEPTOR; PHTHALIC ACID; PHTHALIC ACID BENZYL BUTYL ESTER; PHTHALIC ACID BIS(2 ETHYLHEXYL) ESTER; PHTHALIC ACID DIBUTYL ESTER; PLASTICIZER; TAMOXIFEN;

APOPTOSIS; BREAST CANCER; CELL PROLIFERATION; CELL STRAIN MCF 7; CHEMOTHERAPY; CONFERENCE PAPER; FOOD PACKAGING; HUMAN; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; BREAST NEOPLASMS; CELL PROLIFERATION; COSMETICS; FEMALE; HUMANS; PHTHALIC ACIDS; TAMOXIFEN; TUMOR CELLS, CULTURED;

MINK CELL FOCUS-FORMING VIRUS;

EID: 8444237811     PISSN: 15287394     EISSN: None     Source Type: Journal    
DOI: 10.1080/15287390490514750     Document Type: Conference Paper

References (34)

1. Abu-Qare, A. W., and Abou-Donia, M. B. 2001. Biomarkers of apoptosis: Release of cytochrome c, activation of caspase-3, induction of 8-hydroxy-2′-deoxyguanosine, increased 3-nitrotyrosine, and alteration of p53 gene. J. Toxicol. Environ. Health B 4:313-332.
2. Ahlborg, U. G., Lipworth, L., Titus-Ernstoff, L., Hsieh, C-C., Hanberg, A., Baron, J., Trichopoulos, D., and Adami, H.-O. 1995. Organochlorine compounds in relation to breast cancer, endometrial cancer, and endometriosis: An assessment of the biological and epidemiological evidence. Crit. Rev. Toxicol. 25:463-531.
3. Andersen, H. R., Andersson, A.-M., Arnold, S. F., Autrup, H., Barfoed, M., Beresford, N. A., Bjerregaard, P., Christiansen, L. B., Gissel, B., Hummel, R., Jorgensen, E. B., Korsgaard, B., Le Guevel, R., Leffers, H., McLachlan, J., Moller, A., Nielsen, J. B., Olea, N., Oles-Karasko, A., Pakdel, F., Pedersen, K. L., Perez, P., Skakkeboek, N. E., Sonnenschein, C., Soto, A. M., Sumpter, J. P., Thorpe, S. M., and Grandjean, P. 1999. Comparison of short-term estrogenicity tests for identification of hormone-disrupting chemicals. Environ. Health Perspect. 107:89-108.
4. Choi, S. M., and Lee, B. M. 2004. An alternative mode of action of endocrine-disrupting chemicals and chemoprevention. J. Toxicol. Environ. Health B. (In press).
5. Choi, S. M., Yoo, S. D., and Lee, B. M. 2004. Toxicological characteristics of endocrine-disrupting chemicals: Developmental toxicity, carcinogenicity, and mutagenicity. J. Joxicol. Environ. Health B 7:1-24.
6. Colborn, T., vom Saal, F. S., and Soto, A. M. 1993. Developmental effects of endocrine-disrupting chemicals in wildlife and humans. Environ. Health Perspect. 101:378-384.
7. DeRosa, C., Richter, P., Pohl, H., and Jones, D. E. 1998. Environmental exposures that affect the endocrine system: Public health implications. J. Toxicol. Environ. Health B 1:3-26.
8. Furr, B. J. A., and Jordan, V. C. 1984. The pharmacology and clinical uses of tamoxifen. Pharmacol. Ther. 25:127-205.
9. Gavrieli, Y., Sherman, Y., and Ben-Sasson S. A. 1992. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell Biol. 119:493-501.
10. Gelmann, E. P. 1996. Tamoxifen induction of apoptosis in estrogen receptor-negative cancers: New tricks for an old dog? JNCI 88:224-226.
11. Hahm, H. A., and Davidson, N. E. 1998. Apoptosis in the mammary gland and breast cancer. Endocrine-Related Cancers 5:199-211.
12. Harris, C. A., Henttu, P., Parker, M. G., and Sumpter, J. P. 1997. The estrogenic activity of phthalate esters in vitro. Environ. Health Perspect. 105:802-811.
13. Hashimoto, Y., Kawaguchi, M., Miyazaki, K., and Nakamura, M. 2003. Estrogenic activity of tissue conditioners in vitro. Dent. Mater. 19:341-346.
14. Huang, Y., Ray, S., Reed, J. C., Ibrado, A. M., Tang, C., Nawabi, A., and Bhalla, K. 1997. Estrogen increases intracellular p26Bcl-2 to p21Bax ratios and inhibits taxol-induced apoptosis of human breast cancer MCF-7 cells. Breast Cancer Res. Treat. 42:73-81.
15. Jobling, S., Reynolds, T., White, R., Parker, M. G., and Sumpter, J. P. 1995. A variety of environmentally persistent chemicals, including some phthalate plasticizers, are weakly estrogenic. Environ. Health Perspect. 103:582-587.
16. Jung, M. Y., Kwon, S. K., and Moon, A. 2001. Chemopreventive allylthiopyridazine derivatives induce apoptosis in SK-Hep-1 hepatocarcinoma cells through a caspase-3-dependent mechanism. Eur. J. Cancer. 37:2103-2109.
17. Kiess, W., and Gallaher, B. 1998. Hormonal control of programmed cell death/apoptosis. Eur. J. Endocrinol. 138:482-491.
18. Kobayashi, T., Ruan, S., Clodi, K., Kliche, K. O., Shiku, H., Andreeff, M., and Zhang, W. 1998. Overexpression of Bax gene sensitizes K562 erythroleukemia cells to apoptosis induced by selective chemotherapeutic agents. Oncogene 16:1587-1591.
19. Kroemer, G. 1997. The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nature Med. 3:614-620.
20. Licun, W., and Tannock, I. F. 2003. Selective estrogen receptor modulators as inhibitors of repopulation of human breast cancer cell lines after chemotherapy. Clin. Cancer Res. 9:4614-4618.
21. Love, R. R. 1989. Tamoxifen therapy in primary breast cancer: Biology, efficacy, and side effects. J. Clin. Oncol. 7: 803-815.
22. Mandlekar, S., Yu, R., Tan, T. H., and Kong, A. N. 2000. Activation of caspase-3 and c-Jun NH2-terminal kinase-1 signaling pathways in tamoxifen-induced apoptosis of human breast cancer cells. Cancer Res. 60:5995-6000.
23. Marshall, E. 1998. Tamoxifen. "A big deal," but a complex hand to play. Science 280:196.
24. Nayfield, S. G. 1995. Tamoxifen's role in chemoprevention of breast cancer: An update. J. Cell Biochem. Suppl. 22:42-50.
25. Oltvai, Z. N., Milliman, C. L., and Korsmeyer, S. J. 1993. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74:609-619.
26. Perry, R. R., Kang, Y., and Greaves, B. 1995. Effects of tamoxifen on growth and apoptosis of estrogen-dependent and -independent human breast cancer cells. Ann. Surg. Oncol. 2:238-245.
27. Peyrade, F., Frenay, M., Etienne, M-C., Ruch, F., Guillemare, C., Francois, E., Namer, M., Ferrero, J. M., and Milano, G. 1996. Age-related differences in tamoxifen disposition. Clin. Pharmacol. Ther. 59:401-406.
28. Picard, K., Lhuguenot, J. C., Lavier-Canivenc, M. C., and Chagnon, M. C. 2001. Estrogenic activity and metabolism of n-butyl benzyl phthalate in vitro: Identification of the active molecule(s). Toxicol. Appl. Pharmacol. 172:108-118.
29. Safe, S. H. 2000. Endocrine disruptors and human health - Is there a problem? An update. Environ. Health Perspect. 108:487-493.
30. Soto, A. M., Sonnenschein, C., Chung, K. L., Fernandez, M. F., Olea, N., and Serrano, F. O. 1995. The E-SCREEN assay as a tool to identify estrogens: An update on estrogenic environmental pollutants. Environ. Health Perspect. 103:113-122.
31. Teixeira, C., Reed, J. C., and Pratt, M. A. 1995. Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res. 55:3902-3907.
32. Wang, T. T., and Phang, J. M. 1995. Effects of estrogen on apoptotic pathways in human breast cancer cell line MCF-7. Cancer Res. 55:2487-2489.
33. Yang, E., and Korsmeyer, S. J. 1996. Molecular thanatopsis: A discourse on the BCL2 family and cell death. Blood 88:386-401.
34. Zhang, G. J., Kimijima, I., Onda, M., Kanno, M., Sato, H., Watanabe, T., Tsuchiya, A., Abe, R., and Takenoshita, S. 1999. Tamoxifen-induced apoptosis in breast cancer cells relates to down-regulation of bcl-2, but not bax and bcl-X(L), without alteration of p53 protein levels. Clin. Cancer. Res. 5:2971-2977.